These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12043067)

  • 1. [A plea for an individualized therapy regimen. Which is the optimal dose?].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():26-7. PubMed ID: 12043067
    [No Abstract]   [Full Text] [Related]  

  • 2. [Managing side effects. Individualized dosage makes indinavir more tolerable].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():84. PubMed ID: 15011605
    [No Abstract]   [Full Text] [Related]  

  • 3. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 4. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 6. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
    Cressey TR; Leenasirimakul P; Jourdain G; Tod M; Sukrakanchana PO; Kunkeaw S; Puttimit C; Lallemant M
    J Antimicrob Chemother; 2005 Jun; 55(6):1041-4. PubMed ID: 15883177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination study of Invirase and Norvir starting.
    AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361633
    [No Abstract]   [Full Text] [Related]  

  • 9. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
    Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome associated with use of risperidone, ritonavir, and indinavir: a case report.
    Lee SI; Klesmer J; Hirsch BE
    Psychosomatics; 2000; 41(5):453-4. PubMed ID: 11015640
    [No Abstract]   [Full Text] [Related]  

  • 11. Ritonavir/indinavir combination study shows promising dosing results.
    AIDS Patient Care STDS; 1998 Feb; 12(2):146-7. PubMed ID: 11361915
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir.
    Vandercam B; Moreau M; Horsmans C; Gala JL
    Infection; 1998; 26(5):313. PubMed ID: 9795794
    [No Abstract]   [Full Text] [Related]  

  • 13. Different combinations of ritonavir-indinavir.
    TreatmentUpdate; 2001 Sep; 13(5):1-2. PubMed ID: 11768859
    [No Abstract]   [Full Text] [Related]  

  • 14. [Indinavir-associated lipodystrophy].
    Krautheim A
    Praxis (Bern 1994); 1999 Feb; 88(7):285-7. PubMed ID: 10097649
    [No Abstract]   [Full Text] [Related]  

  • 15. [Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():18-21. PubMed ID: 11373769
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
    J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Highlights from CROI 2002. Individualized therapy for promoting adherence].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():45. PubMed ID: 12049063
    [No Abstract]   [Full Text] [Related]  

  • 18. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 19. [New formulation--fewer tablets--optimal effect].
    Krankenpfl J; 2005; 43(7-10):249. PubMed ID: 16515318
    [No Abstract]   [Full Text] [Related]  

  • 20. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.